- Home
- News
Refine by
Medical Industry News: This-Month
6 news found
Confo Therapeutics today reported preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), with findings presented at ENDO 2026. The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed to target ...
Confo Therapeutics today reported preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), with findings presented at ENDO 2026. The data support CFTX-2034 as a potential first-in-class PBH therapy and advance the program toward IND-enabling studies.CFTX-2034 is a long-acting, highly selective agonistic antibody designed to target ...
In hygienic processing lines such as spray-drying and powder production, residues on hard-to-reach surfaces can lead to contamination risks, product loss, and costly downtime. Alfa Laval today announces the launch of the Controlled Rotating Retractors to effectively remove residues and contaminants from ducts, pipes, tanks and enclosed areas.From Kolding, Denmark, the introduction of these ...
June 9, 2026, Austin, TX — Zetagen Therapeutics, a clinical-stage biopharmaceutical company focused on therapies for primary and metastatic breast cancer, today reported preliminary topline results from its Phase 2a open-label study evaluating ZetaMet (Zeta BC 003) in metastatic breast cancer with lytic bone lesions. The study indicates cessation of tumor activity in treated vertebral bodies and ...
Publication date: 9 June 2026. Zetagen Therapeutics announces the MBC-003 ph2a preliminary results to be featured in an ASCO abstract for 2026.About Zetagen TherapeuticsFounded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs. The ...
Corify Care announced the ACORYS-AI4AF clinical trial at Mayo Clinic, initiating the first U.S. evaluation of instant Global Cardiac Mapping for atrial fibrillation (AF) treatment using the ACORYS system. The study will assess how the 4D FAST-MAP technology supports clinical decision-making in AF ablation.The trial will determine whether ACORYS can identify patients likely to benefit from ...